Aflibercept

27 trials 10 recruiting SOphthalmology & ENT

Filter these 27 trials by condition, phase, country and more.

Open in Search →

27 Registered trials

10 Recruiting

17 Completed trials

20 Sponsors

23 Countries

Phase III

Phase II

Phase IV

Phase III: 16 Phase II/III: 2 Phase II: 4 Phase III/IV: 2 Phase IV: 3

Oversight events:

10 corrective measures across 2 trials

View oversight register →

Indications tested

Neovascular age-related macular degeneration 7 Age-related macular degeneration 2 Retinopathy of prematurity 2 Colorectal cancer metastatic 2 Retinal vein occlusion 2 Macular telangiectasia 1 Diabetic retinopathy 1 Choroid melanoma 1

Sponsors using this IMP

Bayer AG 3 Eyepoint Inc. 3 Medical University Of Graz 3 Alvotech Swiss AG 2 Eyebiotech Limited 2 4d Molecular Therapeutics Inc. 1 AbbVie Deutschland GmbH & Co. KG 1 Centre Hospitalier Universitaire De Dijon 1 Centre Hospitalier Universitaire De Nantes 1 Fondation A De Rothschild 1 Fondation Franc.Cancerologie Digestive 1 IRCCS Istituto Nazionale Tumori Fondazione Pascale 1

All trials — page 2

27 total

MULTICENTER RANDOMIZED PHASE II STUDY COMPARING THE EFFECTIVENESS AND TOLERANCE OF AVELUMAB VERSUS STANDARD 2nd LINE TREATMENT CHEMOTHERAPY … Ended

2024-517362-41-00 Phase II 1 country Fondation Franc.Cancerologie Digestive
Neovascular glaucoma prevention by intravitreal injections of anti-VEGF in patients treated by protontherapy in case of large choroid melano… Ended

2024-513746-11-00 Phase III 1 country Centre Hospitalier Universitaire De Nice
A Clinical Trial to compare Efficacy, Safety, Tolerability of RBS-001 to Eylea® in Subjects with Neovascular Age-Related Macular Degeneratio… Ended

2023-509206-29-00 Phase III 4 countries Rophibio Inc.

Showing 25–27 of 27 trials

← All drugs A–Z